Recombinant activated factor VII given within 4 hours of intracerebral hemorrhage reduced hematoma growth

Basile, Vincenzo S.; Silver, Frank L.
September 2005
ACP Journal Club;Sep/Oct2005, Vol. 143 Issue 2, p34
Academic Journal
The article presents an answer to a question related to the reduction of hematoma growth due to recombinant activated factor VII (rFVIIa) given within 4 hours of intracerebral hemorrhage. In this study, 63% of patients were treated within 3 hours after symptom onset. Growth in the volume of ICH was reduced more by rFVIIa than placebo. Among specific rFVIIa dose groups, the highest dose but not the lower doses or 80 reduced the volume of ICH more than placebo. The relatively small number of patients in this trial may account for imbalances in baseline characteristics, which may have biased the results in favor of treatment.


Related Articles

  • Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain. van Seventer, Robert; Serpell, Michael; Bach, Flemming W.; Morlion, Bart; Zlateva, Gergana; Bushmakin, Andrew G.; Cappelleri, Joseph C.; Nimour, Meryem // Health & Quality of Life Outcomes;2011, Vol. 9 Issue 1, p17 

    Background: The objective of this study is to use the pain numeric rating scale (NRS) to evaluate associations between change in pain severity and changes in sleep, function, and mood assessed via patient-reported outcomes (PROs) in patients with posttraumatic pain. Methods: This is a secondary...

  • Effect of Intravenous Albumin Administration on HEMATOM Volume after Hemorrhagic Stroke. Ehsan Mohammadianinejad, Seyed; majdinasab, Nastaran; Shalilahmadi, Davood; Shirali, Amir; Oghbaei, Morteza // Jundishapur Scientific Medical Journal;2013, Vol. 12 Issue 4, p1 

    Background and Objective: The aim of this study was to evaluate the effect of albumin in hematom volume after hemorrhagic stroke. Subjects and Methods: The study was conducted in a randomized clinical trial; patients with hemorrhagic stroke in 24 hours of onset were included. Patients were...

  • AVM resection after radiation therapy—clinico-morphological features and microsurgical results. Asgari, Siamak; Bassiouni, Hischam; Gizewski, Elke; van de Nes, Johannes A. P.; Stolke, Dietmar; Sandalcioglu, Ibrahim Erol // Neurosurgical Review;Jan2010, Vol. 33 Issue 1, p53 

    A subgroup of patients initially treated by radiosurgery underwent surgical resection because of recurrent hemorrhage or neurological deterioration. In a retrospective study, we want to analyze the clinical features of these patients and evaluate the effect of microneurosurgery in such rare...

  • Histopathological analysis of intracerebral hemorrhage: implications for clinical management. Holling, Markus; Jeibmann, Astrid; Fischer, Bernhard; Albert, Friedrich; Ebel, Heinrich; Paulus, Werner; Stummer, Walter // Acta Neurochirurgica;Mar2012, Vol. 154 Issue 3, p439 

    Background: The clinical impact of routine neuropathologic examination of samples from patients with intracerebral hemorrhage (ICH) is unclear. Methods: Therefore, we evaluated a consecutive series of 378 surgical specimens from patients with ICH concerning demographic data, localization of...

  • Symmetrical thalamic and cerebellar hemorrhages following scorpion envenomation. Kumar, Tekke Praveen; Reddy, V. Umamaheswara; Narayan, Putcha Deekshanthi; Agrawal, Amit // International Journal of Students' Research;2014, Vol. 4 Issue 1, p15 

    Clinical manifestations following scorpion envenomation are a result of autonomic outburst and direct actions of toxin on various systems. Involvement of central nervous system (CNS) following scorpion envenomation is rare. Encephalopathy, cerebral edema, subarachnoid hemorrhage, nonhemorrhagic...

  • Influence of the Placebo Effect upon the Healing Process. Squire, Carol // Positive Health;Apr2002, Issue 75, p27 

    Focuses on the influence of placebo effect in the healing process. Dependence of allopathic medicine to the placebo response; Assumption on the therapeutic effects of the placebo; Belief of the patient to the effectivity of a placebo.

  • Ethical questions over clinical use of placebo.  // Australian Journal of Pharmacy;May2009, Vol. 90 Issue 1068, p79 

    The article highlights some ethical questions over the clinical use of placebo treatments.

  • Rate of anticoagulant-associated intracerebral hemorrhage quintuples.  // Formulary;Apr2007, Vol. 42 Issue 4, p218 

    The article discusses the results of the study regarding the case of anticoagulant-associated intracerebral hemorrhage (ICH). According to an observational study published in the journal "Neurology," the rate of anticoagulant-associated ICH has increased since 1988. The case of ICH has been...

  • Risk of Thromboembolism in Patients Treated with Recombinant Factor VIIa for Warfarin-Associated Hemorrhages of the Central Nervous System. Fink, Matthew E. // Neurology Alert;Aug2010, Vol. 28 Issue 12, p95 

    The article discusses research on the risk of thromboembolism in patients who received recombinant Factor VIIa (rFIIa), a rapidly acting hemostatic agent that reduces the international normalized ratio (INR) and lessens the growth of hematoma, for hemorrhages of the central nervous system...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics